Treatment.com AI Inc. has rebranded and reincorporated as Rocket Doctor AI (AIDR:CSE; TREIF:OTC; 939:FRA) to to better represent the company’s core focus on AI-driven administrative, diagnostic, clinical decision support, and referral solutions that empower both healthcare professionals and patients, the company noted in an August 18 release.
The new name was effective and began trading on the Canadian Securities Exchange under the ticker AIDR last week.
The rebrand brings together the Global Library of Medicine (GLM), a proprietary, clinician-curated AI knowledge base, with Rocket Doctor Inc.'s digital health marketplace and platform. Together, they create a scalable suite of AI-enhanced diagnostic and clinical support tools that empower physicians to practice independently while expanding access to care across North America. Leveraging large language models, connected medical devices, and proprietary software, the combined platform is designed to improve efficiency for providers and extend high-quality healthcare to rural, remote, and underserved populations, including patients on Medicaid and Medicare in the United States. The move builds on the successful acquisition of Rocket Doctor Inc. in April 2025, marking a crucial step toward commercialization and delivering measurable value to patients, providers, and shareholders.
"We are very excited about this next chapter for the company," Treatment.com AI Chief Executive Officer Dr. Essam Hamza said before the change. "This name change marks a natural step in uniting our technology and service offerings under a single, stronger identity. Following the acquisition of Rocket Doctor Inc., we are at an important inflection point. As we move toward the next phase of commercialization and prepare for our Q2 announcement, we remain focused on delivering practical, AI-driven, clinically validated, scalable solutions and keeping our shareholders informed of our progress."
According to the company, Rocket Doctor AI Inc. addresses the challenge of diagnostic accuracy, efficiency, and equity in healthcare by providing AI-driven decision support built on the proprietary physician-curated GLM. The GLM is designed to reduce administrative burden, support clinicians in making safer, faster decisions, and help strengthen medical education through AI-simulated clinical training. Rocket Doctor Inc. solves the problem of access to care by enabling physicians to run independent virtual or hybrid practices through its digital health platform. It connects patients, including those in rural, underserved, or Medicaid/Medicare populations, to physicians using advanced digital tools and remote monitoring devices. Together, the two platforms have the opportunity to create a comprehensive, end-to-end solution: from AI-powered intake, triage, and clinical decision support, to virtual care delivery and post-visit follow-up. This combination is intended to improve efficiency for providers, expand patient access, and create scalable models of care that can be deployed across North America.
The new stock symbol, AIDR, is intended to better reflect the company's core focus on AI-driven administrative, diagnostic, clinical decision support, and referral solutions that empower healthcare professionals and patients alike.
Dr. William Cherniak, CEO of Rocket Doctor, noted at the time of the acquisition, "It's been a fast-paced journey since joining the team at Treatment.com AI. We couldn't be more thrilled to take the ethos and brand brought from our work across North America to now jointly power Rocket Doctor AI. There's much more to go in our work of improving physicians' practice of medicine, while in parallel increasing access to care for patients in need; this refined name makes clear our focus on technology as a critical component to achieving these objectives."
AI Engine Developed by Hundreds of Professionals
With input from hundreds of healthcare professionals globally, Treatment.com AI developed a comprehensive, personalized healthcare AI engine, the GLM. With over 10,000 expert medical reviews, the GLM is built to deliver clinically validated information and support to healthcare professionals, as well as recommended tests (physical and lab), imaging, and billing codes.
The GLM is developed by clinicians to help healthcare professionals (doctors, nurses, or pharmacists) reduce their administrative burden, create more time for necessary face-to-face patient appointments, and ensure greater consistency in the quality of patient support.
John Newell said, "For speculative investors, the stock offers a technical setup with clearly defined upside targets. We view Rocket Doctor AI at current levels of CA$0.60 and US$0.45 as a Speculative Buy."
Now Rocket Doctor Inc., has introduced a new virtual health screening program for adults over 60 in partnership with EngageWell IPA.
This initiative, called the Healthy Aging Program, is supported by a five-year, US$1 million grant from the CVS Health Foundation and aims to enhance healthcare access for older adults in New York City.
The program offers free virtual screenings for heart health, cognitive and memory function, and mental health.
Board-certified physicians conduct consultations via phone or video and provide personalized follow-up care plans. Community Health Workers assist participants in navigating and accessing necessary local services. Medicaid patients can use the service at no cost, while Medicare patients are covered through insurance.
Analyst: 'Shopify for Physicians'
*Market veteran John Newell of John Newell & Associates on August 25 looked at the company's charts and noted, "Volume has been steadily increasing as higher lows form, a classic signal of accumulation."
"The stock is transitioning from a prolonged consolidation into a confirmed reversal phase," Newell wrote. "Volume patterns, Fibonacci retracement support, and momentum indicators all argue for the likelihood of higher targets being reached in sequence. The Point of Recognition (POR) appears to have formed, suggesting institutional and retail buyers are beginning to re-enter."
Newell continued, "For speculative investors, the stock offers a technical setup with clearly defined upside targets. We view Rocket Doctor AI at current levels of CA$0.60 and US$0.45 as a Speculative Buy."
*On May 21, Technical Analyst Clive Maund released an evaluation of Treatment.com AI Inc., emphasizing the company's strategic placement within the rapidly changing artificial intelligence (AI) healthcare sector.
Maund pointed out that the company has crafted a platform designed by physicians to tackle inefficiencies in healthcare by integrating clinical intelligence, virtual care features, and voice assistant technology into a cohesive system. He highlighted the company's diagnostic tools as providing continuous availability and AI-driven voice interactivity to aid clinical workflows.
He also likened Rocket Doctor Inc. to a "Shopify for physicians," which enables practitioners to set up remote clinics and broaden access to virtual care. Maund noted the model's scalability as a key factor in its significance to the wider telehealth market.
The Catalyst: Telehealth Major Part of Last 5 Years
The virtual care and telehealth sector remained in a period of transition during mid-2025, as stakeholders navigated increasing regulatory pressures, operational scrutiny, and efforts to redefine ethical practices across the industry.
On April 3, Fierce Healthcare published a retrospective analysis examining how the COVID-19 pandemic reshaped healthcare delivery in the United States.
Jesse Ehrenfeld, M.D., immediate past president of the American Medical Association, emphasized that "you can't have a conversation about the last five years and not talk about telehealth."
He noted a dramatic rise in adoption, with three-quarters of physicians offering telehealth by late 2023, compared to only one-quarter before the pandemic. Fierce Healthcare reported that this expansion improved access to care, especially for mental health services and patients in remote areas, and encouraged broader use of patient portals. However, experts like Patricia McGaffigan of the Institute for Healthcare Improvement advised that adoption must remain measured, stating, "it's important for us to proceed with a reasonable level of enthusiasm, but also a clear degree of caution."
The introduction of artificial intelligence tools into telehealth also has drawn attention.
According to Ehrenfeld, "AI is coming into practice in a way that is really exciting," citing a 78% increase in physician usage of health-related AI tools from 2023 to 2024. Yet, regulatory gaps and concerns around responsible implementation continued. Fierce Healthcare noted that general-purpose AI models were sometimes used for clinical decisions, raising questions about patient safety and oversight.
According to a June 12 report from Future Market Insights, the global wireless healthcare asset management market was projected to increase from US$52.06 billion in 2025 to US$155.40 billion by 2035. The report attributed this growth to the widespread adoption of artificial intelligence (AI), Internet of Things (IoT), and real-time tracking tools within hospitals.
Streetwise Ownership Overview*
Rocket Doctor AI (AIDR:CSE; TREIF:OTC; 939:FRA)
These technologies were used to monitor high-value equipment such as infusion pumps and surgical instruments, improve maintenance scheduling, and enhance patient safety through predictive analytics. The report also noted that cloud-based platforms enabled real-time equipment monitoring, predictive maintenance, and compliance tracking. It identified a trend toward integrating AI systems with electronic health records (EHRs) and hospital information systems (HIS) to support resource optimization and more informed clinical decisions.
Ownership and Share Structure
According to Refinitiv, insiders own approximately 5% of the newly branded Rocket Doctor AI.
Institutions own nearly 1%.
Retail investors own the remaining 94%.
The company has 80.38 million outstanding common shares. Its market cap was approximately CA$55.47 million at close on August 26.
Over the past 52 weeks, the company traded between CA$0.33 and CA$0.85 per share.
| Want to be the first to know about interesting Healthcare Services and Technology investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rocket Doctor AI.
- Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
* Disclosure for the quote from the John Newell article published on August 25, 2025
- For the quoted article (published on August 25, 2025), the Company has paid Street Smart, an affiliate of Streetwise Reports, US$2,000.
- Author Certification and Compensation: [John Newell of John Newell and Associates] was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Newell holds a Chartered Investment Management (CIM) designation (2015) and a U.S. Portfolio Manager designation (2015). The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.
John Newell Disclaimer
As always it is important to note that investing in precious metals like silver carries risks, and market conditions can change violently with shock and awe tactics, that we have seen over the past 20 years. Before making any investment decisions, it's advisable consult with a financial advisor if needed. Also the practice of conducting thorough research and to consider your investment goals and risk tolerance.
* Disclosure for the quote from the Clive Maund article published on May 21, 2025
- For the quoted article (published on May 21, 2025), the Company has paid Street Smart, an affiliate of Streetwise Reports, US$1,500.
- Author Certification and Compensation: [Clive Maund of clivemaund.com] is being compensated as an independent contractor by Street Smart, an affiliate of Streetwise Reports, for writing the article quoted. Maund received his UK Technical Analysts’ Diploma in 1989. The recommendations and opinions expressed in the article accurately reflect the personal, independent, and objective views of the author regarding any and all of the designated securities discussed. No part of the compensation received by the author was, is, or will be directly or indirectly related to the specific recommendations or views expressed
Clivemaund.com Disclosures
The quoted article represents the opinion and analysis of Mr. Maund, based on data available to him, at the time of writing. Mr. Maund's opinions are his own, and are not a recommendation or an offer to buy or sell securities. As trading and investing in any financial markets may involve serious risk of loss, Mr. Maund recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction and do your own due diligence and research when making any kind of a transaction with financial ramifications. Although a qualified and experienced stock market analyst, Clive Maund is not a Registered Securities Advisor. Therefore Mr. Maund's opinions on the market and stocks cannot be only be construed as a recommendation or solicitation to buy and sell securities.
